UCB Acquires Candid Therapeutics
May 3, 2026
UCB has agreed to acquire Candid Therapeutics, a clinical-stage biotechnology company focused on T-cell engagers for autoimmune and inflammatory diseases, for up to $2.2 billion including $2.0 billion upfront. Two River and Vida Ventures, part of the Bellco Health ecosystem, highlighted their roles in founding and early development of Candid following the announced acquisition.
- Buyers
- UCB
- Targets
- Candid Therapeutics
- Industry
- Biotechnology
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
United Therapeutics Acquires Thymmune Therapeutics
July 3, 2026
Biotechnology
United Therapeutics announced it has acquired Thymmune Therapeutics, a privately held preclinical-stage biotechnology company developing thymic regenerative cell therapies. The deal includes $140 million paid in cash upfront, plus potential earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031.
-
Biogen Acquires RayThera for Up to $1 Billion to Expand Immunology Pipeline
June 18, 2026
Healthcare Services
Biogen entered into a definitive agreement to acquire RayThera, a private immunology-focused biotechnology company, for total consideration of up to $1 billion driven by an upfront payment plus clinical and regulatory milestone payments. The deal is expected to close in the third quarter of 2026, with Biogen taking over development, manufacturing, and global commercialization of RayThera’s small-molecule anti-inflammatory assets.
-
UCB To Acquire Candid Therapeutics for Up to $2.2 Billion
May 3, 2026
Biotechnology
UCB, a global biopharmaceutical company, has signed a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion. The deal includes $2.0 billion in upfront payments and up to $200 million in potential milestone payments, and is expected to close by the end of Q2 or early Q3 2026, subject to antitrust clearance and customary conditions.
-
Rallybio Corporation Acquires Candid Therapeutics
March 5, 2026
Biotechnology
Rallybio Corporation entered into a definitive agreement to acquire clinical-stage biotechnology company Candid Therapeutics in a merger transaction. The combined company will operate as Candid Therapeutics, Inc. and is expected to trade on Nasdaq under the ticker symbol CDRX, with the deal targeted to close in mid-2026 subject to customary conditions and approvals. Concurrently, Candid arranged an oversubscribed private financing of more than $505 million from a syndicate of healthcare institutional investors and mutual funds, expected to fund operations through 2030.
-
AbbVie Acquires Celsius Therapeutics
June 27, 2024
Biotechnology
AbbVie has acquired Celsius Therapeutics, a Cambridge-based clinical-stage biotechnology company, for $250 million in cash. The acquisition adds Celsius' lead anti-TREM1 antibody candidate CEL383 to AbbVie’s inflammatory disease pipeline to support development for inflammatory bowel disease (IBD).
-
UCB Acquires Engage Therapeutics
June 5, 2020
Pharmaceuticals
Belgium-based biopharma UCB has acquired Summit, New Jersey-based Engage Therapeutics for an upfront cash payment of US$125 million plus up to US$145 million in milestone payments, gaining worldwide rights to Staccato Alprazolam. The acquisition adds a late-stage, drug-device rescue therapy candidate for epilepsy to UCB's neurology portfolio and includes updated license and supply agreements with Alexza Pharmaceuticals.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.